Jasper Therapeutics, Inc.
JSPR
Positions held
Your positionsJSPR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $18.63M | Enterprise value | — | Trailing P/E | — | Forward P/E | -0.22 |
| PEG | — | Price / book | 11.20 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | none | Mean target | $20.00 |
| 52w high | $2.69 | 52w low | $0.32 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$2.8M | -$1.2M | -$9.1M | -$18.7M | -$26.7M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.2M | -$11.0M | -$15.8M | -$19.2M | -$27.1M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$75.8M | -$71.3M | -$64.5M | -$37.7M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$83.9M | -$76.2M | -$68.9M | -$51.2M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
2026-09-15 · Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
2026-09-09 · Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-17 · Jasper Therapeutics beats Q2 expectations but shares fall after results
2026-08-14 · Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-12 · Piper Sandler Initiates Jasper Therapeutics With Overweight Rating, $2 Price Target
2026-07-17 · Jasper gets a lifeline in merger with immune drugmaker Kira
2026-07-16 · Jasper Therapeutics Completes Merger With Kira Pharmaceuticals, Shares Fall
Price (daily)
Full chart · RSI · MACD · patterns